MEDICUS PHARMA LTD. Research and Development Expense
MEDICUS PHARMA LTD. (MDCX) reported Research and Development Expense of $4.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- MEDICUS PHARMA LTD. research and development expense for the quarter ending 2026-06-30 was $4.91M, a 240.92% increase year-over-year.
- MEDICUS PHARMA LTD. research and development expense for the quarter ending 2026-03-31 was $2.70M, a 34.80% increase year-over-year.
- MEDICUS PHARMA LTD. research and development expense for the quarter ending 2025-12-31 was $2.59M, a 89.79% increase year-over-year.
- MEDICUS PHARMA LTD. research and development expense for the quarter ending 2025-09-30 was $1.68M, a 198.64% increase year-over-year.
- MEDICUS PHARMA LTD. research and development expense for fiscal 2025 was $7.72M, a 118.87% increase from fiscal 2024.
- MEDICUS PHARMA LTD. research and development expense for fiscal 2024 was $3.53M, a 1722.41% increase from fiscal 2023.
- MEDICUS PHARMA LTD. research and development expense for fiscal 2023 was $193.58K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.91M 10-Q · filed 2026-08-12 | $7.61M 10-Q · filed 2026-08-12 | $10.20M derived: sum of 3 quarters · filed 2026-08-12 | $11.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-14 | $5.30M derived: sum of 2 quarters · filed 2026-05-14 | $6.98M derived: sum of 3 quarters · filed 2026-05-14 | $8.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.28M derived: sum of 2 quarters · filed 2026-03-25 | $5.72M derived: sum of 3 quarters · filed 2026-08-12 | $7.72M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.68M 10-Q · filed 2025-11-14 | $3.12M derived: sum of 2 quarters · filed 2026-08-12 | $5.13M 10-Q · filed 2025-11-14 | $6.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.44M 10-Q · filed 2026-08-12 | $3.45M 10-Q · filed 2026-08-12 | $4.81M derived: sum of 3 quarters · filed 2026-08-12 | $5.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.01M 10-Q · filed 2026-05-14 | $3.37M derived: sum of 2 quarters · filed 2026-05-14 | $3.94M derived: sum of 3 quarters · filed 2026-05-14 | $5.21M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.93M derived: sum of 2 quarters · filed 2026-03-25 | $3.21M derived: sum of 3 quarters · filed 2026-03-25 | $3.53M 10-K · filed 2026-03-25 |
| 2024-09-30 | $564.14K 10-Q · filed 2025-11-14 | $1.84M derived: sum of 2 quarters · filed 2025-11-14 | $2.16M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $1.28M 10-Q · filed 2025-08-11 | $1.60M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $321.38K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $193.58K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |